12:00 AM
Feb 07, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

(-)-desmethylsibutramine (DMS): Began Phase I testing

Knoll Pharmaceutical Co. (Mount Olive, N.J.) markets racemic sibutramine under the name Meridia to treat obesity.


Read the full 79 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >